5-Amino-1MQ Reconstitution Calculator

Research Use

Calculate precise U-100 syringe units, concentration (mg/mL), and doses per vial for 5-Amino-1MQ research.

Clinical Precision Tool

5-Amino-1MQ Dosage Calculator

U-100 Calibrated
Calculated Syringe Draw
20.0Units
➜ 0.200 mL volume
0 Units100 Units Max
Concentration
25.00 mg/mL
Tick Marks
20.0 ticks
OE
Written by OnePeptideShip Editorial Team
Reviewed by Dr. Aris Thorne, MD, Board Certified Endocrinology Advisor
Updated September 2026

Clinical Pharmacology & Mechanism of Action

5-Amino-1MQ (5-amino-1-methylquinolinium) is a highly specialized, small, membrane-permeable molecule. Unlike most items in the "peptide" category which are chains of amino acids, 5-Amino-1MQ is a chemical compound specifically designed to inhibit an enzyme known as Nicotinamide N-methyltransferase (NNMT).

NNMT is an enzyme heavily implicated in obesity, metabolic syndrome, and cellular aging. In obese individuals, NNMT levels in white adipose tissue (fat cells) are massively elevated.

NNMT drains the body's natural stores of NAD+ (a critical coenzyme for cellular energy).

By selectively blocking the NNMT enzyme, 5-Amino-1MQ forces the body into a state of metabolic hyper-efficiency:

  • NAD+ Restoration: It naturally raises cellular NAD+ levels without requiring external precursors like NMN or NR .
  • Shrinking White Adipose Tissue: It fundamentally alters the metabolism of fat cells, shrinking their size and reducing overall fat mass without suppressing appetite.
  • Muscle Preservation: Clinical studies in mice demonstrated that NNMT inhibition not only reduced fat but actually promoted the proliferation of muscle stem cells, preserving lean mass during weight loss.

Pharmacokinetics & Administration

5-Amino-1MQ is unique because it is orally bioavailable. The vast majority of researchers administer it via oral capsules (typically 50mg to 150mg per day).

However, injectable liquid suspensions of 5-Amino-1MQ (often combined in "lipo" stacks) have gained massive popularity for their higher bioavailability and localized effects. The injectable form requires precise reconstitution math, as it comes in high-milligram vials (e.g., 50mg or 100mg).

Standard Injectable Research Dosing Protocols

For subcutaneous injection research, the bioavailable dose is much lower than the oral capsule dose.

  • Dosage: 5.0mg to 10.0mg per day.
  • Frequency: Once daily (can be taken at any time of day, though morning is preferred due to mild stimulatory effects from increased NAD+).
  • Cycle Duration: Typically run for 8 to 12 weeks.

Reconstitution Math & Syringe Guide

Because 5-Amino-1MQ is dosed in milligrams (mg) rather than micrograms, calculating the syringe units is straightforward but critical to avoid injecting massive volumes of liquid.

Step-by-Step Reconstitution (50mg Vial)

  1. Swab the rubber stoppers of your 50mg 5-Amino-1MQ vial and your Bacteriostatic Water.
  2. Using a sterile mixing syringe, draw exactly 2mL of Bacteriostatic Water.
  3. Inject the water slowly down the inside wall of the vial.
  4. Swirl gently until the compound is completely dissolved.

The Math for a Standard Dose (5.0mg):

  • 50mg total in the vial.
  • You added 2mL of water.
  • Therefore, the concentration is 25mg per 1mL.
  • You need a 5.0mg dose. Divide the dose by the concentration: 5.0 ÷ 25 = 0.2mL.
  • 0.2mL = 20 units on a U-100 syringe.

(For a 10.0mg dose: 10.0 ÷ 25 = 0.40mL, which is 40 units).

Common Mistakes & Troubleshooting

  • Confusing Oral vs Injectable Doses: Oral capsules are usually 50mg each because the digestive tract destroys a significant portion of the molecule. If a researcher attempts to inject 50mg (based on oral protocols), they will severely overdose and rapidly deplete the vial.
  • Taking it Before Bed: The massive restoration of cellular NAD+ and ATP production often leads to a noticeable increase in physical energy. Injecting it late at night can cause insomnia.
  • Failing to Hydrate: Increased cellular metabolism requires increased water intake. Headaches are a common side effect if hydration is not maintained.

Medical & Research Disclaimer

The information provided on this page, including all calculations, is for educational and laboratory research purposes only. It does not constitute medical advice. Peptides mentioned here are not approved for human consumption outside of FDA-approved clinical trials unless specified otherwise. Always consult a licensed healthcare provider before undertaking any new therapy.

Frequently Asked Questions

Using a 50mg vial with 2mL of BAC water (25mg/mL): 5mg = 0.2mL = 20 units on a U-100 syringe. For a 10mg dose, draw 0.4mL = 40 units.

NNMT (Nicotinamide N-methyltransferase) is an enzyme that consumes NAD+ precursors to methylate nicotinamide. In obese subjects, NNMT is chronically overactivated in fat cells, draining the cellular NAD+ pool and contributing to the metabolic dysfunction that makes obesity hard to reverse. By inhibiting NNMT, 5-Amino-1MQ restores NAD+ levels naturally, activates AMPK and SIRT1 (both longevity/metabolism enzymes), and directly reduces the lipid content of adipocytes.

They work by different mechanisms. NMN and NR are NAD+ precursors - they supply the raw material to make NAD+. 5-Amino-1MQ prevents NAD+ from being wasted by NNMT - it's like plugging a drain instead of running more water. In research, 5-Amino-1MQ can be more effective than NMN/NR alone because it prevents the system from destroying the NAD+ that's already there. Many researchers stack all three.

GLP-1 drugs (Semaglutide, Tirzepatide) work in the brain - they suppress appetite so you eat less. 5-Amino-1MQ works directly in the fat cells and mitochondria - it forces the body to burn fat more efficiently and raises the basal metabolic rate. It does NOT suppress appetite. This makes the two mechanisms highly complementary: GLP-1s create the caloric deficit, while 5-Amino-1MQ ensures that deficit comes primarily from fat rather than muscle or metabolic slowdown.

Yes. Research in animal models showed that NNMT inhibition not only reduced fat mass but also promoted muscle stem cell (satellite cell) proliferation, suggesting a muscle-preserving and even muscle-building effect. This is a major differentiator from GLP-1 drugs, which can cause significant muscle catabolism in large caloric deficits.

Injectable form has significantly higher bioavailability because it bypasses first-pass metabolism in the liver. A 5-10mg injectable dose is typically equivalent in effect to a 50-75mg oral capsule dose, making injectable form far more dose-efficient. However, oral is much more convenient and comfortable. Research is ongoing to establish definitive bioavailability comparisons in humans.

Most injectable research protocols run 8 to 12 weeks, with 1-3 injections per week depending on dosing frequency. Because it is not a hormone or receptor agonist, there is no evidence of receptor desensitization, meaning extended cycles may be feasible. However, prudent research practice includes periodic blood work to monitor liver enzymes and NAD+ metabolites.

Related Research Calculators